This is a contrast between Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) and CRISPR Therapeutics AG (NASDAQ:CRSP) based on their analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership. The two companies are Biotechnology and they also compete with each other.
Earnings and Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Biohaven Pharmaceutical Holding Company Ltd.||51||0.00||43.78M||-8.95||0.00|
|CRISPR Therapeutics AG||59||0.00||34.37M||-0.46||0.00|
Table 1 shows the gross revenue, earnings per share and valuation for Biohaven Pharmaceutical Holding Company Ltd. and CRISPR Therapeutics AG.
Table 2 has Biohaven Pharmaceutical Holding Company Ltd. and CRISPR Therapeutics AG’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Biohaven Pharmaceutical Holding Company Ltd.||86,028,689.33%||0%||0%|
|CRISPR Therapeutics AG||58,512,087.16%||-2.6%||-2%|
The Current Ratio and a Quick Ratio of Biohaven Pharmaceutical Holding Company Ltd. are 9 and 9. Competitively, CRISPR Therapeutics AG has 8.3 and 8.3 for Current and Quick Ratio. Biohaven Pharmaceutical Holding Company Ltd.’s better ability to pay short and long-term obligations than CRISPR Therapeutics AG.
Recommendations and Ratings for Biohaven Pharmaceutical Holding Company Ltd. and CRISPR Therapeutics AG can be find in next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Biohaven Pharmaceutical Holding Company Ltd.||0||1||1||2.50|
|CRISPR Therapeutics AG||0||0||3||3.00|
$63 is Biohaven Pharmaceutical Holding Company Ltd.’s average target price while its potential upside is 20.11%. CRISPR Therapeutics AG on the other hand boasts of a $72 average target price and a 10.16% potential upside. The information presented earlier suggests that Biohaven Pharmaceutical Holding Company Ltd. looks more robust than CRISPR Therapeutics AG as far as analyst opinion.
Insider and Institutional Ownership
Institutional investors owned 91.92% of Biohaven Pharmaceutical Holding Company Ltd. shares and 46.8% of CRISPR Therapeutics AG shares. Insiders owned roughly 10.4% of Biohaven Pharmaceutical Holding Company Ltd.’s shares. Comparatively, 0.4% are CRISPR Therapeutics AG’s share owned by insiders.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Biohaven Pharmaceutical Holding Company Ltd.||-4.31%||20.97%||33%||-13.83%||27.86%||48.32%|
|CRISPR Therapeutics AG||1%||49.37%||59.3%||63.07%||101.48%||153.31%|
For the past year Biohaven Pharmaceutical Holding Company Ltd.’s stock price has smaller growth than CRISPR Therapeutics AG.
Biohaven Pharmaceutical Holding Company Ltd. beats on 7 of the 11 factors CRISPR Therapeutics AG.
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. Its advanced product candidate includes rimegepant, which is intended to initiate two Phase III clinical trials for the acute treatment of migraine; and trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia. The company also develops BHV-3500 for the prevention of chronic and episodic migraine; BHV-0223 for the treatment of amyotrophic lateral sclerosis, a neurodegenerative disease that affects nerve cells in the brain and spinal cord; and BHV-5000 for the treatment of symptoms associated with Rett syndrome, such as breathing irregularities. Biohaven Pharmaceutical Holding Company Ltd. was founded in 2013 and is based in New Haven, Connecticut. Biohaven Pharmaceutical Holding Company Ltd. is a subsidiary of Portage Biotech Inc.
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9)gene-editing platform in Switzerland. The CRISPR/Cas9 technology allows for changes to genomic DNA. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies. The company also has research collaboration agreements with Neon Therapeutics and Massachusetts General Hospital Cancer Center to develop novel T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.